The offering provides near-term liquidity to address the company's negative working capital position ($15.4M current assets vs $28.0M current liabilities) and reduces debt by $5.25M, but at the cost of significant dilution (~35% increase in share count). Monitor the company's cash burn rate and progress toward the planned DrugSorb-ATR De Novo submission in early 2027, as the FDA denial in April 2025 remains a key overhang. The insider participation (96,527 shares at $5.18) provides some alignment but does not offset the dilutive impact.
Drug in focus
CTSO drug pipeline →CytoSorb
▼ Bearish Named in this 424B5- Impact
- Phase
- Approved / Commercialized
- Time to market
- Already on the market (CE-marked in Europe, FDA-cleared in US)
- Next catalyst
- None dated
What to watchWatch the September 28, 2026 Nasdaq compliance deadline, if CTSO cannot sustain $1.00 for 10 consecutive trading days before then, delisting risk becomes acute. The DrugSorb-ATR FDA De Novo submission (submitted Q1 2026) is a potential positive catalyst but has no announced decision date. The stock is a high-risk micro-cap with limited cash runway and stagnant revenue.
Price Chart
How similar events traded
Executive Summary
CytoSorbents is conducting a registered direct offering of 653,208 shares of common stock (including 96,527 shares to directors and officers at $5.18/share) and pre-funded warrants for 151,822 shares at $4.939/warrant, with gross proceeds of approximately $4.0 million. Concurrently, the company is issuing 202,429 registered shares to Avenue Venture Opportunities Fund to satisfy $1.0 million of debt, part of a broader $5.25 million debt restructuring under the Avenue Amendment. Net cash proceeds of ~$3.5 million will be used to repay $3.0 million of Avenue principal plus fees, with the remainder for working capital. The offering follows Q3 2026 earnings reported 8 days prior, which showed +3% YoY revenue growth and improved net loss, and represents a dilutive capital raise at a $14M market cap.
Key Financial Metrics
Key Facts
- Registered direct offering of 556,681 shares at $4.94/share and 96,527 shares to insiders at $5.18/share, plus pre-funded warrants for 151,822 shares at $4.939/warrant
- Gross proceeds of approximately $4.0 million; net proceeds of ~$3.5 million after fees and expenses
- Concurrent issuance of 202,429 registered shares to Avenue to satisfy $1.0 million of debt; total $2.25 million debt-for-equity swap under Avenue Amendment
- Cash repayment of $3.0 million principal plus $322,500 in fees to Avenue; total debt reduction of ~$5.25 million
- Shares outstanding post-offering: 4,261,562 (excluding pre-funded warrant exercise), up from 3,152,889 as of September 30, 2026
- Dilution of $4.92 per share for new investors at $4.94 offering price; as adjusted net tangible book value of $0.02/share
- H.C. Wainwright & Co. acting as placement agent with 6.0% cash fee and warrants for 18,078 shares at $6.175/share
- Company had $5.7 million cash on hand as of September 30, 2026, with current liabilities of $28.0 million exceeding current assets of $15.4 million
- Q3 2026 revenue of $9.7M (+3% YoY) and net loss of $1.8M, improving from $3.2M loss in Q3 2025
- Market cap of $14M; offering represents ~29% of pre-offering market cap in gross proceeds
Financial Impact
Gross proceeds of $4.0 million from equity offering; $2.25 million of debt converted to equity; net cash proceeds of ~$3.5 million after fees; total debt reduction of ~$5.25 million
Risk Factors
- Immediate and substantial dilution of ~$4.92 per share for new investors; share count increases by ~35% from 3.15M to 4.26M
- Company had negative working capital of $12.6M as of September 30, 2026, and requires additional financing to fund operations
- FDA denied DrugSorb-ATR De Novo application in April 2025; resubmission planned for early 2027 with uncertain outcome
- Up to $19.4M available under ATM facility could lead to further dilution
- Low market cap ($14M) and high volatility (11.3% normal daily move) amplify price sensitivity to this dilutive event
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001104659-26-130444 |
| Document: 0001104659-26-130444-index-headers.html | 0001104659-26-130444 |
| Document: 0001104659-26-130444-index.html | 0001104659-26-130444 |
| Document: 0001104659-26-130444.txt | 0001104659-26-130444 |
Track record
12 reports on CTSO
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +36.94% at T+60 after the Aug 6, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 20, 20261d ago 424B5 Bearish 6/10 Viewing Entry $5.39 Now $4.16 +22.82% settles Feb 19
- Nov 20, 20261d ago 8-K Bearish 6/10 Entry $5.39 Now $4.16 +22.82% settles Feb 19
- Nov 19, 20262d ago 8-K/A Neutral 4/10 Entry $5.13 Now $4.16 −18.91% settles Feb 18
- Nov 17, 20265d ago NT 10-Q Neutral 4/10 Entry $4.52 Now $4.16 −7.96% settles Feb 16
- Nov 12, 20269d ago Press Release Neutral 4/10 Entry $4.87 Now $4.16 −14.58% settles Feb 11
- Nov 12, 20269d ago 8-K Neutral 5/10 No price data
- Sep 23, 20268w ago 8-K Mixed 5/10 Entry $4.91 Now $4.16 −15.27% settles Dec 17
- Aug 6, 202615w ago Press Release Bearish 6/10 Entry $0.3600 to $0.2270 Now $4.16 −1055.56% ▲ +36.94% +34.68% vs SPY
- Jun 25, 202621w ago DEFA14A Neutral 3/10 Entry $0.3620 to $0.2660 Now $4.16 +1049.17% ▼ −26.52% −32.61% vs SPY
- Jun 16, 202622w ago Insider Cluster Bullish 6/10 Entry $0.5189 to $0.3205 Now $4.16 +701.70% ▼ −38.23% −40.10% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers